SummaryRMgm-4661
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption, Introduction of a transgene |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 31283102 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | P. berghei ANKA 507cl1 (RMgm-7) |
Other information parent line | P.berghei ANKA 507cl1 (RMgm-7) is a reference ANKA mutant line which expresses GFP under control of a constitutive promoter. This reference line does not contain a drug-selectable marker (PubMed: PMID: 16242190). |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Wall RJ, Tewari R |
Name Group/Department | School of Life Sciences, Queens Medical Centre |
Name Institute | University of Nottingham |
City | Nottingham |
Country | London |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-4661 |
Principal name | ∆MyoE |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not different from wild type |
Fertilization and ookinete | Not different from wild type |
Oocyst | Not different from wild type |
Sporozoite | Normal oocyst production. ∆MyoE parasites had a higher number of midgut sporozoites and a reduced number of salivary gland sporozoites compared with the WT‐GFP control. Nevertheless, salivary gland sporozoites were able to infect mice as effectively as the control WT‐GFP parasites. Despite a significant decrease in salivary gland sporozoites, these sporozoites were found to have normal motility. |
Liver stage | Not different from wild type |
Additional remarks phenotype | Mutant/mutation Phenotype However, ∆MyoE parasites had a higher number of midgut sporozoites and a reduced number of salivary gland sporozoites compared with the WT‐GFP control. Nevertheless, salivary gland sporozoites were able to infect mice as effectively as the control WT‐GFP parasites. Despite a significant decrease in salivary gland sporozoites, these sporozoites were found to have normal motility. We used live cell imaging to detect expression of each protein throughout the life cycle and to examine their location. The Class XIV myosins were detected predominantly in the invasive stages (developing merozoites in schizonts and merozoites, ookinetes, and developing sporozoites within oocysts and sporozoites). As shown previously, MyoA‐GFP was associated with the surface pellicle of each invasive stage, whereas MyoB‐GFP was localised as an apical end dot in merozoites, mature (>20 hr) ookinetes, and late stage sporozoites. MyoE‐GFP was detected as a dot at the basal end of ookinetes and sporozoites and as a dot in merozoites. MyoE‐GFP was also expressed in liver stages, but as with merozoites, it was not possible to clearly identify the basal end of these stages. MyoF‐GFP was most abundant in the insect stages, particularly ookinetes and oocysts. In mature ookinetes, MyoF‐GFP was restricted to the apical end, whereas in oocysts, it was more evenly distributed throughout the developing sporozoites. In contrast, MyoJ‐GFP was only observed in mature oocysts, located at the junction between the differentiating sporozoites and the oocyst bodies. Following oocyst rupture, MyoJ‐GFP remained associated with the oocyst body and was not present in sporozoites. Finally, MyoK‐GFP was found exclusively associated with the nucleus of gametocytes, appearing as an arc across the cell, and in zygotes/early ookinetes, as two distinctive dots. These dots were either absent or only remnants were seen in mature ookinetes.
Analyses of mutants expressing tagged myosins provide evidence for the following: - distinct spatio‐temporal profiles for each myosin during ookinete development - Colocalisation of myosins with MyoA and the apical marker, ISP1 (PBANKA_1209400; inner membrane complex sub-compartment protein 1)
Other mutants
|
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_0112200 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0613900 | ||||||||||||||||||||||||
Gene product | myosin E | ||||||||||||||||||||||||
Gene product: Alternative name | MyoE | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | |||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
![]() Primer information: Primers used for amplification of the target sequences
![]()
| |||||||||||||||||||||||||
top of page |
top of page | |||||||||||||||||||
Type and details of transgene | |||||||||||||||||||
Is the transgene Plasmodium derived | Transgene: not Plasmodium | ||||||||||||||||||
Transgene name | GFP (gfp-mu3) | ||||||||||||||||||
top of page | |||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||
Inducable system used | No | ||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||
Type of plasmid/construct | (Linear) plasmid double cross-over | ||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||
Selectable marker used to select the mutant parasite | gfp (FACS) | ||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||
Selection (positive) procedure | FACS (flowsorting) | ||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||
Additional remarks genetic modification | |||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||
top of page | |||||||||||||||||||
Other details transgene | |||||||||||||||||||
top of page | |||||||||||||||||||
Promoter | |||||||||||||||||||
Gene Model of Parasite | PBANKA_1133300 | ||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1357100 | ||||||||||||||||||
Gene product | elongation factor 1-alpha | ||||||||||||||||||
Gene product: Alternative name | eef1a | ||||||||||||||||||
| |||||||||||||||||||
top of page | |||||||||||||||||||
3'-UTR | |||||||||||||||||||
Gene Model of Parasite | PBANKA_0719300 | ||||||||||||||||||
Gene product | bifunctional dihydrofolate reductase-thymidylate synthase, putative | ||||||||||||||||||
Gene product: Alternative name | dhfr/ts | ||||||||||||||||||
| |||||||||||||||||||
Insertion/Replacement locus | |||||||||||||||||||
Replacement / Insertion | Replacement locus | ||||||||||||||||||
Gene Model of Parasite | PBANKA_0306000 | ||||||||||||||||||
Gene product | 6-cysteine protein | ||||||||||||||||||
Gene product: Alternative name | 230p | ||||||||||||||||||
| |||||||||||||||||||
top of page |